For instance, tamoxifen, a selective ER modulator that binds to ERs and suppresses estrogen action, was found to significantly increase body mass index (30.9 on average, indicative of obesity), visceral fat area, and incidence of type 2 diabetes in women with breast cancer64. This evidence concerns the gene ESR1 and obesity due to melanocortin 4 receptor deficiency.